RGXTF yields 10582.01% · JNJ yields 2.13%● Live data
📍 RGXTF pulled ahead of the other in Year 1
Combined, RGXTF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RGXTF + JNJ for your $10,000?
Regenx Tech Corp. engages in the exploration and development of mineral properties, and the development and deployment of extraction technologies in Spain and North America. The company has an option acquire interest in the Aroche Wollastonite Project that consists of five mining grids covering approximately 150 hectares located in the province of Huelva, southwestern Spain. It also develops HM X-mill, a mineral grinding mill for grinding of ores, as well as regrinding of concentrates and tailings; HM X-leach, a cyanide-free process for the extraction of gold and other precious metals; and HM X-tract, a modular turnkey portable processing unit that includes crushing, grinding, sizing, gravity separation, floatation, concentration, clarification, water recycling, power generation, and operational service support modules. The company was formerly known as Mineworx Technologies Ltd. and changed its name to Regenx Tech Corp. in October 2022. Regenx Tech Corp. was incorporated in 2017 and is based in St. Albert, Canada.
Full RGXTF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.